Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-01
2005-11-01
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S492000, C424S649000
Reexamination Certificate
active
06960596
ABSTRACT:
The present invention relates to therapeutic associations for the treatment of cancer, comprising an effective amount of a camptothecin, or a camptothecin derivative, with an effective amount of an alkylating agent such as a platin derivative, and methods of using such therapeutic associations.
REFERENCES:
patent: 4473692 (1984-09-01), Miyasaka et al.
patent: 4545880 (1985-10-01), Miyasaka et al.
patent: 6191119 (2001-02-01), Rubinfeld
patent: 0 056 692 (1982-07-01), None
patent: 0 074256 (1983-03-01), None
patent: 0 088 642 (1983-09-01), None
patent: 0 296 612 (1988-12-01), None
patent: 0 321 122 (1989-06-01), None
patent: 0 325 247 (1989-07-01), None
patent: 0 540 099 (1993-05-01), None
patent: 0 715 854 (1996-06-01), None
patent: 0 737 686 (1996-10-01), None
patent: 57-116074 (1982-07-01), None
patent: 59-5188 (1984-01-01), None
patent: 59-51289 (1984-03-01), None
patent: 60-19790 (1985-01-01), None
patent: 1-246287 (1989-10-01), None
patent: 1-249777 (1989-10-01), None
patent: 57-116015 (1992-07-01), None
patent: WO 90/03169 (1990-04-01), None
patent: WO 93/09782 (1993-05-01), None
patent: WO 96/37496 (1996-11-01), None
patent: WO 96/38146 (1996-12-01), None
patent: WO 96/38449 (1996-12-01), None
T.H. Corbett et al., “Evaluation of Single Agents and Combinations of Chemotherapeutic Agents in Mouse Colon Carcinomas,”Cancer, 40(5):2660-2680 (1977).
T.H. Corbett et al., “Response of Transplantable Tumors of Mice to Anthracenedione Derivatives Alone and in Combination with Clinically Useful Agents,”Cancer Treatment Reports, 66(5):1187-1200 (May 1982).
David L. Emerson et al., “In vivo Antitumor Activity of Two New Seven-substituted Water-soluble Camptothecin Analogues,”Cancer Research, 55:603-609 (Feb. 1995).
Isabelle Madelaine et al., “Sequential Modifications of Topoisomerase I Activity in a Camptothecin-Resistant Cell Line Established by Progressive Adaptation,”Biochemical Pharmacology, 45(2):339-348 (1993).
Tomio Furuta and Teruo Yokokura, “Combination Therapy of CPT-11, a Camptothecin Derivative, with Various Antitumor Drugs Against L1210 Leukemia,”Japanese Journal of Cancer and Chemotherapy, 18(3):393-402 (Mar. 1991); English Abstract p. 402.
C.K. Mirabelli, et al., “A Murine Model to Evaluate the Ability of in Vitro Clonogenic Assays to Predict the Response to Tumors in Vivo”,Cancer Research, Official Journal of the American Association for Cancer Research, 48(19):5447-5454 (Oct. 1, 1998).
Boku et al.,J. Clin. Oncol. 79(5/6):984-990 (1999) Abstract Only.
Sugiyama et al.,Cancer Lett. (Shannon, Irel.), 128(2):211-218, (1998) Abstract Only.
Kobayashi et al.,Cancer Chemother. Pharmcol., 42(1):53-58, (1998) Abstract Only.
Abstract: Japio No. 00965715 for JP 57-116015.
Abstract: Japio No. 00965774 for JP 57-116074.
Abstract: Japio No. 01293588 for JP 59-5188.
Abstract: Japio No. 01541290 for JP 60-19790.
Abstract: Japio No. 02948687 for JP 1-246287.
Abstract: Japio No. 02952177 for JP 1-249777.
Abstract: Derwent No. 01984-110813/198418 for JP 59-051289.
Masahiro Fukuoka and Noriyuki Masuda, “Clinical Studies of Irinotecan Alone and in Combination with Cisplatin,”Cancer Chemotherap. Pharmacology, 34(Suppl):S105-S111 (1994).
Kensei Tobinai et al., “Combination Phase I/II Study of Irinotecan Hydrochloride (CPT-11) and Carboplatin in Relapsed or Refractory Non-Hodgkin's Lymphoma,”Jpn. J. Clin. Oncol., 26(6):455-460 (1996).
A. Yokoyama et al., “Phase I/II Study of Irinotecan (CPT-11) and Cisplatin (P) Plus Concurrent Thoracic Radiation Therapy (TRT) in Stage III Non-Small Cell Lung Cancer (NSCLC: A Japan Clinical Oncology Group (JCOG) Trial,”Proc. Am. Soc. Clin. Oncol., 15(-):407 AB:1242 (1996).
Aventis Pharma S.A.
Cook Rebecca
Gupta Balaram
LandOfFree
Composition comprising camptothecin or a comptothecin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition comprising camptothecin or a comptothecin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition comprising camptothecin or a comptothecin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3514447